The kit was created during their time as undergraduates under the mentorship of Qi, a CRISPR/Cas9 researcher. Qi believes that college students are critical in making biotechnologies within the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

For those who are new to the company, we have a focus in cardiovascular diseases with in vivo gene editing and where we take the CRISPR/Cas9 components ... towards c-Kit or CD117 and then we ...

This valuable study reports on the critical role of ANKRD5 (ANKEF1) in sperm motility and male fertility. However, the supporting data remain incomplete. This work will be of interest to biomedical ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...